Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Abstract Background and Aim Previous smaller meta‐analyses comparing the incidence of
hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir …

Importance Conventional meta-analyses with aggregated study-level data have yielded
conflicting results for the comparative effectiveness of tenofovir disoproxil fumarate vs …

Background and aims Antiviral agents for chronic hepatitis B (CHB) reduced the risk of
hepatocellular carcinoma (HCC) development. The outcomes of entecavir (ETV), tenofovir …

Hepatitis B virus (HBV) is the one of most common causes of the hepatocellular carcinoma
(HCC), especially in eastern world. The aim of this review is to try to understand the …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

There is a strong association between the distribution of Hepatitis B virus (HBV) carriers and
the incidence of hepatocellular carcinoma (HCC). About 60% of HCC in Japan is caused by …

Background: Long-term therapy with nucleos (t) ide analogs (NAs) such as entecavir (ETV)
and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular …

Simple Summary We developed a novel risk-scoring model for hepatocellular carcinoma
development in treatment-naïve patients with chronic hepatitis B virus infection who are …

Introduction Oral nucleos (t) ide analogues (NUCs) are recommended as first-line therapy
for chronic hepatitis B (CHB) due to higher HBV-DNA suppression rates and safety profile …